NCT07460206 2026-03-10
PRELUDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
Clinical Trials
3 trialsNCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting